🎉 M&A multiples are live!
Check it out!

Elevation Oncology Valuation Multiples

Discover revenue and EBITDA valuation multiples for Elevation Oncology and similar public comparables like Vivoryon Therapeutics, Julphar, and Pharming.

Elevation Oncology Overview

About Elevation Oncology

Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.


Founded

2019

HQ

United States of America
Employees

34

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$44.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Elevation Oncology Financials

Elevation Oncology has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Elevation Oncology achieved revenue of n/a and an EBITDA of -$40.4M.

Elevation Oncology expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Elevation Oncology valuation multiples based on analyst estimates

Elevation Oncology P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$41.4M -$40.4M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$95.1M -$45.7M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Elevation Oncology Stock Performance

As of April 15, 2025, Elevation Oncology's stock price is $0.

Elevation Oncology has current market cap of $17.4M, and EV of -$44.7M.

See Elevation Oncology trading valuation data

Elevation Oncology Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$44.7M $17.4M XXX XXX XXX XXX $-0.74

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Elevation Oncology Valuation Multiples

As of April 15, 2025, Elevation Oncology has market cap of $17.4M and EV of -$44.7M.

Elevation Oncology's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Elevation Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Elevation Oncology and 10K+ public comps

Elevation Oncology Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$44.7M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 1.1x XXX XXX XXX
P/E -0.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Elevation Oncology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Elevation Oncology Valuation Multiples

Elevation Oncology's NTM/LTM revenue growth is n/a

Elevation Oncology's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Elevation Oncology's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Elevation Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Elevation Oncology and other 10K+ public comps

Elevation Oncology Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -2% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Elevation Oncology Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Elevation Oncology M&A and Investment Activity

Elevation Oncology acquired  XXX companies to date.

Last acquisition by Elevation Oncology was  XXXXXXXX, XXXXX XXXXX XXXXXX . Elevation Oncology acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Elevation Oncology

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Elevation Oncology

When was Elevation Oncology founded? Elevation Oncology was founded in 2019.
Where is Elevation Oncology headquartered? Elevation Oncology is headquartered in United States of America.
How many employees does Elevation Oncology have? As of today, Elevation Oncology has 34 employees.
Who is the CEO of Elevation Oncology? Elevation Oncology's CEO is Mr. Joseph J. Ferra, Jr.
Is Elevation Oncology publicy listed? Yes, Elevation Oncology is a public company listed on NAS.
What is the stock symbol of Elevation Oncology? Elevation Oncology trades under ELEV ticker.
When did Elevation Oncology go public? Elevation Oncology went public in 2021.
Who are competitors of Elevation Oncology? Similar companies to Elevation Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Elevation Oncology? Elevation Oncology's current market cap is $17.4M
Is Elevation Oncology profitable? Yes, Elevation Oncology is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.